#Canada #Toronto #PharmaNutra #SiderAL #Sigma Lifesciences

PharmaNutra S.p.A. Partners with Sigma Lifesciences in Canada

PharmaNutra S.p.A., an Italian leader in nutritional supplements, has recently taken a significant step to bolster its presence in North America through a new distribution agreement with Canadian pharmaceutical firm Sigma Lifesciences. This collaboration marks an important milestone for PharmaNutra as it expands its market reach to Canada and introduces its innovative SiderAL® products into this evolving market.

The agreement, finalized on November 26, 2024, includes the distribution of key dietary supplements such as SiderAL® Forte, SiderAL® Folic, and SiderAL® Drops, all formulated using PharmaNutra's patented Sucrosomial® Technology. This advanced delivery system ensures that micronutrients like iron are both protected and effectively absorbed by the body, addressing common issues related to tolerability. These products are instrumental for individuals seeking nutritional support, particularly in the areas of iron supplementation.

The collaboration with Sigma Lifesciences adds another feather in the cap of PharmaNutra, which has already established its presence across over 80 countries since its inception in 2003 by founders Andrea and Roberto Lacorte. In addition to the SiderAL® line, the agreement also encompasses Ultramag®, a supplement based on Sucrosomial® Magnesium known for its high bioavailability and effectiveness. Notably, both Ultramag® and the SiderAL® range have been officially registered by Health Canada, paving the way for their commercialization.

In preparation for the product launch scheduled for the second quarter of 2025, a training session was organized by PharmaNutra’s Scientific and Commercial Management team for Sigma Lifesciences staff. This session, conducted in Toronto, featured engagement with more than thirty pharmacists and doctors from various medical fields, including Gynecology, Hematology, Internal Medicine, and Oncology. The aim was to deepen understanding of Sucrosomial® Technology and gather insights on local market needs.

Carlo Volpi, COO of PharmaNutra, expressed optimism regarding this partnership, highlighting Canada's vast potential as a lucrative market for their innovative supplements. He emphasized that Sigma Lifesciences, being a well-respected entity in the healthcare space, will significantly contribute to PharmaNutra's growth trajectory in Canada. He stated, "This agreement is crucial as it completes our North American presence, and we are confident about the positive impact our products, rooted in patented technology, will have."

As PharmaNutra forges ahead with this promising engagement, it aims not only to expand its footprint in Canada but also to connect more effectively with healthcare professionals and consumers in the region. This collaborative endeavor underscores PharmaNutra's commitment to delivering high-quality nutritional supplements that cater to specific health requirements, reinforcing its status as a key player in the global health and nutrition sector.

The future looks bright for PharmaNutra in Canada as it prepares to unveil its innovative products in one of North America’s key markets. With a growing portfolio and a robust distribution network through Sigma Lifesciences, PharmaNutra is set to make waves in the Canadian health supplement industry.